Cargando…
Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences
The utilization of the monoclonal antibodies (mAbs) as therapeutic agents is one of the most favourable fields in immunotherapy. The immunogenicity of mAbs is one of the major parameters that may restrict their therapeutic and diagnostic applications. Rituximab, a chimeric mAb against CD20, is attac...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707678/ https://www.ncbi.nlm.nih.gov/pubmed/36124508 http://dx.doi.org/10.4103/ijmr.IJMR_312_19 |